SERMs Drug-Drug Interaction Table: A Complete Prescriber Reference

What Is the SERMs Drug Class?

Selective estrogen receptor modulators are a structurally diverse group of compounds that bind the estrogen receptor (ER) alpha and beta subtypes but produce tissue-specific agonist or antagonist effects depending on local co-regulator expression. They are not estrogens. Their pharmacological signatures diverge enough that prescribers should treat each agent as pharmacokinetically distinct rather than interchangeable.

Approved Agents and Their Primary Indications

The six SERMs with meaningful US clinical use are:

| SERM | FDA Indication(s) | Primary Metabolism | |---|---|---| | Tamoxifen | ER-positive breast cancer; DCIS; chemoprevention | CYP2D6 (to endoxifen), CYP3A4 | | Raloxifene | Osteoporosis; breast cancer risk reduction | UGT1A1, UGT1A8, UGT1A10 | | Clomiphene citrate | Anovulatory infertility | CYP2D6, CYP3A4 (partial) | | Enclomiphene citrate | Hypogonadotropic hypogonadism in men (investigational/compounded) | CYP3A4 (predominant) | | Ospemifene | Dyspareunia; vulvovaginal atrophy | CYP2C9, CYP3A4 | | Bazedoxifene | Menopausal vasomotor symptoms (with conjugated estrogens) | UGT1A |

Mechanism Differences That Drive Distinct DDI Profiles

Tamoxifen is a prodrug. Its active metabolite endoxifen is generated primarily by CYP2D6, making any CYP2D6 inhibitor or inducer clinically significant [1]. Raloxifene bypasses the cytochrome P450 system almost entirely, relying on UGT glucuronidation, so its interaction list is shorter. Ospemifene is metabolized by both CYP2C9 and CYP3A4, which makes it susceptible to a wider range of azole antifungals and rifamycins than raloxifene. Enclomiphene and its racemate clomiphene act centrally at the hypothalamus to block estrogen negative feedback, thereby stimulating FSH and LH secretion [2].

Tamoxifen Drug-Drug Interactions

Tamoxifen has the most extensive DDI profile of any SERM. The core issue is CYP2D6-dependent bioactivation to endoxifen, the metabolite responsible for the majority of its antitumor effect.

CYP2D6 Inhibitors: The Most Urgent Interaction

The Clinical Pharmacogenomics Implementation Consortium (CPIC) 2021 guideline states: "For patients who are CYP2D6 normal metabolizers prescribed tamoxifen, concomitant use of strong or moderate CYP2D6 inhibitors should be avoided." [1]

Paroxetine reduces endoxifen plasma levels by approximately 65% in CYP2D6 normal metabolizers. Fluoxetine produces a roughly 50% reduction. Bupropion reduces endoxifen by approximately 35 to 45%. These are not theoretical interactions: a population-based study in JAMA (N=2,430) found that women who received paroxetine overlapping with tamoxifen had a significantly higher rate of breast cancer recurrence compared with those who received non-inhibiting antidepressants [3].

Practical management: Substitute sertraline (weak CYP2D6 inhibitor), escitalopram, venlafaxine, or mirtazapine for mood and hot-flash management in tamoxifen patients. Order a CYP2D6 genotype if you are prescribing tamoxifen long-term.

| CYP2D6 Inhibitor | Inhibition Strength | Estimated Endoxifen Reduction | Recommended Action | |---|---|---|---| | Paroxetine | Strong | ~65% | Avoid | | Fluoxetine | Strong | ~50% | Avoid | | Bupropion | Moderate | ~35-45% | Avoid if possible | | Duloxetine | Moderate | ~25-30% | Avoid if possible | | Sertraline | Weak | <15% | Acceptable alternative | | Venlafaxine | Minimal | <10% | Preferred alternative |

CYP3A4 and P-gp Interactions

Tamoxifen is also a CYP3A4 substrate and a P-glycoprotein substrate. Rifampin (300 mg twice daily) reduces tamoxifen AUC by approximately 86% [4]. Strong CYP3A4 inducers such as carbamazepine, phenytoin, and St. John's Wort carry similar risks and should be avoided or replaced with non-inducing alternatives during tamoxifen therapy.

Conversely, tamoxifen itself inhibits CYP2C9 and can raise warfarin levels. The British National Formulary documents a clinically significant INR elevation when tamoxifen is started in anticoagulated patients [5]. Check INR within two weeks of tamoxifen initiation in any patient on vitamin K antagonists.

Tamoxifen and Hormone Therapy

Adding exogenous estradiol to tamoxifen therapy is generally contraindicated in hormone-sensitive malignancy because estradiol competes directly at the estrogen receptor for the same binding site. In men receiving tamoxifen for gynecomastia or off-label testosterone recovery, concurrent estradiol adds no therapeutic benefit and reduces tamoxifen efficacy.

Raloxifene Drug-Drug Interactions

Raloxifene's DDI profile is significantly narrower than tamoxifen's because it does not rely on CYP enzymes for activation or primary clearance.

Warfarin and Coagulation

Raloxifene reduces prothrombin activity by approximately 10% when started in stable warfarin patients [6]. The mechanism is not fully established but may involve modest competition for plasma protein binding. Clinically, this is rarely catastrophic, but an INR check 7 to 10 days after starting raloxifene in anticoagulated patients is appropriate.

Cholestyramine and Bile Acid Sequestrants

Cholestyramine reduces raloxifene absorption by approximately 60% by binding it in the gut lumen [6]. Do not co-administer. If a bile acid sequestrant is clinically necessary, separate dosing by at least four hours and recognize that bioavailability is still likely to be reduced.

Levothyroxine and Systemic Absorption

Raloxifene may reduce levothyroxine absorption similarly to other oral medications that bind in the gut. Space dosing by at least four hours. Recheck TSH six to eight weeks after starting raloxifene in hypothyroid patients on stable levothyroxine.

Enclomiphene and Clomiphene Drug-Drug Interactions

Enclomiphene is the trans-isomer of clomiphene citrate. Commercial clomiphene is a racemic mixture (approximately 38% enclomiphene, 62% zuclomiphene). Enclomiphene is the isomer responsible for gonadotropin stimulation; zuclomiphene has a longer half-life and estrogen-agonist properties that contribute to side effects [2].

HPG Axis Interactions

Any exogenous androgen or estrogen can blunt enclomiphene's mechanism of action. Testosterone replacement therapy suppresses LH and FSH through hypothalamic and pituitary negative feedback, working in exactly the opposite direction from enclomiphene's intended effect. Co-prescribing enclomiphene with testosterone cypionate while expecting HPG axis recovery is pharmacologically contradictory and documented to produce poor LH response [7].

Anabolic-androgenic steroids carry the same caveat. Patients transitioning from testosterone to enclomiphene for spermatogenesis restoration should typically allow four to eight weeks of testosterone washout before enclomiphene is expected to produce meaningful LH/FSH rises, though individual recovery timelines vary.

CYP3A4 Interactions for Enclomiphene

Enclomiphene is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, or ritonavir may increase enclomiphene exposure. Strong inducers such as rifampin or carbamazepine may reduce its exposure and blunt its gonadotropin-stimulating effect. Published pharmacokinetic trials specifically studying these interactions in enclomiphene are limited, so management should follow standard CYP3A4 substrate precautions: avoid strong inhibitors when possible, do not use strong inducers concurrently without monitoring LH/FSH response.

Drug-Class Interactions: GnRH Analogs

GnRH agonists (leuprolide, nafarelin) and GnRH antagonists (cetrorelix, ganirelix) suppress pituitary gonadotropin release directly. They pharmacodynamically antagonize enclomiphene and clomiphene. These combinations should not be used simultaneously in the same treatment protocol.

Ospemifene Drug-Drug Interactions

Ospemifene is prescribed for moderate-to-severe dyspareunia due to vulvovaginal atrophy. Its dual-enzyme metabolism through CYP2C9 and CYP3A4 creates a more complex DDI profile than raloxifene.

CYP2C9 and CYP3A4 Inhibitors

The FDA-approved Osphena prescribing information states that fluconazole (a strong CYP2C9 inhibitor and moderate CYP3A4 inhibitor) increases ospemifene AUC by approximately 2.7-fold [8]. This interaction should be considered clinically significant. Avoid fluconazole and other strong CYP2C9 inhibitors (amiodarone, miconazole) during ospemifene therapy. If a patient requires systemic antifungal treatment, use an agent outside the CYP2C9 pathway if clinically feasible.

Rifampin, a strong inducer of both CYP2C9 and CYP3A4, reduces ospemifene exposure substantially. Concurrent use is not recommended.

Warfarin

Ospemifene is highly protein-bound (greater than 99%). Co-administration with warfarin has the potential for competitive displacement and altered anticoagulant effect. The ospemifene label recommends monitoring coagulation parameters closely when the two drugs are used together [8].

Estrogens and Progestogens

Ospemifene is not indicated for concurrent use with systemic estrogens or progestogens. Its ER-agonist activity in vaginal tissue could interact with systemically delivered estradiol in an additive or unpredictable manner.

Bazedoxifene Drug-Drug Interactions

Bazedoxifene in the US market is available only as part of the conjugated estrogens/bazedoxifene (CE/BZA) combination product (Duavee). Its purpose in that combination is endometrial protection, replacing progestin in menopausal hormone therapy.

UGT Inducers

Bazedoxifene is metabolized almost entirely by UGT glucuronidation (primarily UGT1A). Rifampin, a potent UGT1A inducer, reduces bazedoxifene AUC by approximately 37% at steady state [9]. This is significant because reduced bazedoxifene exposure in CE/BZA therapy means potentially inadequate endometrial protection. Strong UGT1A inducers including carbamazepine, phenytoin, and St. John's Wort may have a similar effect and should not be used with CE/BZA without an alternative endometrial protection strategy.

Protein Binding and Concurrent Medications

Bazedoxifene is highly protein-bound (approximately 98 to 99%). Theoretical displacement interactions exist with other highly protein-bound drugs, though clinical reports of significant pharmacokinetic consequences are sparse in the published literature.

Master DDI Reference Table: All SERMs

The table below consolidates the most clinically significant interactions across the SERM class for rapid prescriber reference.

| SERM | Interacting Drug/Class | Mechanism | Clinical Effect | Management | |---|---|---|---|---| | Tamoxifen | Paroxetine, fluoxetine | CYP2D6 inhibition | Endoxifen reduced ~50-65%; loss of efficacy | Avoid; switch to sertraline or venlafaxine | | Tamoxifen | Bupropion, duloxetine | CYP2D6 inhibition (moderate) | Endoxifen reduced ~25-45% | Avoid if possible | | Tamoxifen | Rifampin | CYP3A4/P-gp induction | Tamoxifen AUC reduced ~86% | Avoid | | Tamoxifen | Carbamazepine, phenytoin | CYP3A4 induction | Reduced tamoxifen exposure | Avoid; use alternative AED | | Tamoxifen | St. John's Wort | CYP3A4/P-gp induction | Reduced tamoxifen exposure | Contraindicated | | Tamoxifen | Warfarin | CYP2C9 inhibition | INR elevation | Check INR at 1-2 weeks | | Tamoxifen | Systemic estrogens | ER competition | Reduced SERM efficacy | Contraindicated in ER+ malignancy | | Raloxifene | Warfarin | Protein binding / unclear | PT reduced ~10% | INR at 7-10 days | | Raloxifene | Cholestyramine | GI binding | Absorption reduced ~60% | Separate by 4+ hours or avoid | | Raloxifene | Levothyroxine | GI binding (possible) | Reduced T4 absorption | Separate by 4+ hours; recheck TSH | | Clomiphene/Enclomiphene | Testosterone/androgens | Pharmacodynamic antagonism | Blunted LH/FSH response | Do not co-administer | | Clomiphene/Enclomiphene | GnRH analogs | Pharmacodynamic antagonism | Pituitary suppression overrides SERM | Do not co-administer | | Clomiphene/Enclomiphene | Strong CYP3A4 inhibitors | CYP3A4 inhibition | Increased enclomiphene exposure | Avoid; monitor if unavoidable | | Clomiphene/Enclomiphene | Strong CYP3A4 inducers | CYP3A4 induction | Reduced enclomiphene exposure; blunted HPG effect | Avoid | | Ospemifene | Fluconazole | CYP2C9/3A4 inhibition | AUC increased ~2.7-fold | Avoid | | Ospemifene | Rifampin | CYP2C9/3A4 induction | Reduced ospemifene exposure | Not recommended | | Ospemifene | Warfarin | Protein displacement | Potential INR change | Monitor coagulation | | Bazedoxifene (CE/BZA) | Rifampin | UGT1A induction | AUC reduced ~37%; inadequate endometrial protection | Avoid | | Bazedoxifene (CE/BZA) | Carbamazepine, phenytoin | UGT1A induction | Reduced bazedoxifene exposure | Avoid; choose non-inducing AED | | Bazedoxifene (CE/BZA) | St. John's Wort | UGT1A induction | Reduced bazedoxifene exposure | Contraindicated |

Pharmacogenomics and the Tamoxifen Decision

CYP2D6 genotype testing is the single highest-yield pharmacogenomic test available for SERM prescribers. The CPIC guideline classifies CYP2D6 phenotypes as poor metabolizer (PM), intermediate metabolizer (IM), normal metabolizer (NM), and ultrarapid metabolizer (UM) [1].

Clinical Phenotype Implications

Poor metabolizers produce very little endoxifen regardless of drug interactions. Their 10-year recurrence data are consistently worse than normal metabolizers on the same tamoxifen dose. A retrospective analysis published in the Journal of Clinical Oncology (N=4,935) found that CYP2D6 PM status was associated with a hazard ratio of 1.27 for breast cancer recurrence compared with NM status (P<0.001) [10].

Ultrarapid metabolizers are a separate concern: they may metabolize tamoxifen so rapidly that endoxifen exposure is paradoxically reduced. Dose escalation to 40 mg daily has been proposed in UMs, though prospective outcome data remain limited.

Actionable Genotype-Guided Substitution

If a patient is a CYP2D6 poor metabolizer or is on an unavoidable strong CYP2D6 inhibitor, consider switching from tamoxifen to an aromatase inhibitor (anastrozole, letrozole, or exemestane) if the patient is postmenopausal and the indication allows. Aromatase inhibitors do not require CYP2D6 bioactivation. This is a concrete, guideline-supported alternative rather than a theoretical one [1].

SERM Prescribing: Monitoring Recommendations by Agent

Tamoxifen Monitoring

Order a baseline CYP2D6 genotype at prescribing. Review the complete medication list for CYP2D6 inhibitors before initiating therapy. Check a baseline INR in patients on warfarin, then recheck at two weeks. Consider measuring plasma endoxifen concentrations (available through specialty pharmacogenomics labs) if polypharmacy cannot be simplified or if the patient has a CYP2D6 IM/PM genotype. A target endoxifen trough above 5.9 ng/mL has been proposed in published pharmacokinetic modeling as associated with better clinical outcomes [11].

Raloxifene Monitoring

Check an INR seven to ten days after starting raloxifene in patients on warfarin. Recheck TSH at six to eight weeks in patients on levothyroxine. No CYP genotyping is required.

Enclomiphene/Clomiphene Monitoring

Check LH and FSH at baseline and at four weeks after initiating therapy. If response is inadequate, review the medication list for androgen co-administration or strong CYP3A4 inducers before escalating dose.

Ospemifene Monitoring

Ask specifically about antifungal use at every visit. Fluconazole is prescribed frequently for vaginal candidiasis, exactly the population receiving ospemifene, making this a real-world, not theoretical, risk. If systemic antifungal therapy is needed, a non-CYP2C9 antifungal (such as topical clotrimazole or systemic anidulafungin) is preferable.

Bazedoxifene (CE/BZA) Monitoring

Ask about antiepileptic drug use and herbal supplement use at every visit, specifically targeting St. John's Wort and rifamycins. Annual endometrial assessment is appropriate in patients with unexplained bleeding regardless of bazedoxifene compliance.